Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial.
Kunio NakamuraZhaonan SunClaire Hara-CleaverKarthik BodhinathanRobin L AvilaPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2024)
NCT00027300URL: https://clinicaltrials.gov/ct2/show/NCT00027300.
Keyphrases
- multiple sclerosis
- placebo controlled
- phase iii
- double blind
- phase ii
- study protocol
- clinical trial
- open label
- image quality
- white matter
- computed tomography
- deep brain stimulation
- dual energy
- contrast enhanced
- phase ii study
- randomized controlled trial
- positron emission tomography
- radiation therapy
- magnetic resonance imaging
- rectal cancer
- locally advanced